Mizuho Maintains Outperform on Verastem, Lowers Price Target to $14
Verastem Q1 Earnings Call Highlights
Verastem, Inc. 2026 Q1 - Results - Earnings Call Presentation
Verastem (VSTM) Q1 2026 Earnings Transcript
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
BTIG Maintains Buy on Verastem, Lowers Price Target to $18
Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript
Verastem Inc (NASDAQ:VSTM) Mixed Q1 Results Disappoint on Revenue Miss
Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Verastem Q1 Adj. EPS $(0.43) Beats $(0.46) Estimate, Sales $18.671M Miss $21.579M Estimate
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Verastem Oncology Rolls Out Its Reimagine Recurrent Low-Grade Serous Ovarian Cancer Campaign For AVMAPKI FAKZYNJA CO-PACK
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
BTIG Reiterates Buy on Verastem, Maintains $19 Price Target
Vectoring In On Verastem
HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
